NHS
Fylde and Wyre
Clinical Commissioning Group

Tocilizumab subcutaneous (RoActemra®▼) for moderate to severe active rheumatoid arthritis

Commissioning Statement

Fylde and Wyre Clinical Commissioning Group has agreed to fund the prescribing of Subcutaneous Tocilizumab for treating active rheumatoid arthritis (RA). This is the preferred formulation option for tocilizumab as an alternative to the intravenous formulation.

It is funded only:

- Where the patient meets the prescribing criteria as set out in NICE technology appraisals for 1st, 2nd and 3rd line use to treat active RA and the agreed Lancashire Rheumatology Alliance flex for use as monotherapy.
- As part of the current Patient Access Scheme (PAS); the discount to be passed on to the CCG
- Where the supply to the patient is through a Homecare delivery service.

This medicine is classified as RED for this indication

Summary of supporting evidence:

- The SUMMACTA study demonstrated the non-inferiority of Tocilizumab s/c against the Tocilizumab IV formulation.
- Tocilizumab s/c demonstrated efficacy and safety profiles comparable with those of Tocilizumab IV with the exception of injection site reactions. However the incident rate of reaction (10.1%) was similar to that reported in studies in patients with RA who received other subcutaneous anti-TNF inhibitors
- Tocilizumab s/c offers innovative administration of an IL-6 inhibitor
- Tocilizumab s/c injection provides an additional, more convenient administration option and opportunity for home injection for patients with RA
- Tocilizumab s/c is expected to be at a reduced cost through a patient access scheme which is commercial in confidence

For details around the evidence, cost effectiveness and for an explanation of the colour classification system please refer to the website of the Lancashire Medicines Management Group at: http://www.lancsmmg.nhs.uk/

The policy will be reviewed earlier than the review date if NICE publishes guidance.

Policy date: September 2014
Review date: September 2017